.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Management of Beta-Thalassemia

EP. 1: Overview of Beta Thalassemia

January 31st 2020

EP. 2: Prevalence and Clinical Presentation of B-Thalassemia

January 31st 2020

EP. 3: β-Thalassemia Severity and Impact on Patients

January 31st 2020

EP. 4: Impact of β-Thalassemia on the Providers

January 31st 2020

EP. 5: Current Approaches for Beta-Thalassemia

January 31st 2020

EP. 6: The Role of Transfusion for Beta-Thalassemia

January 31st 2020

EP. 7: Understanding Transfusion for Beta-Thalassemia

January 31st 2020

EP. 8: Iron Dysregulation & Allogeneic Stem Cell Transplantation

January 31st 2020

EP. 9: Approval of Novel Therapy for Beta-Thalassemia

January 31st 2020

EP. 10: End Points of Phase III Study for Beta-Thalassemia

January 31st 2020

EP. 11: Future Impact of the Novel Therapy for Beta-Thalassemia

January 31st 2020

EP. 12: The Potential for Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 13: The Process for Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 14: The Cost and Safety of Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 15: Pipeline Agents for the Treatment of Beta-Thalassemia

January 31st 2020

EP. 16: Final Thoughts on the Treatment of Beta-Thalassemia

January 31st 2020